22-04-2025
Don't let Big Pharma's out-of-state lobbyists undermine Oklahoma's drug program
Will Rogers once said, 'This country is bigger than Wall Street. If they don't believe it, show 'em the map.' That wisdom is alive in the Oklahoma Legislature, where lawmakers are standing up to Big Pharma ― the $6 trillion pharmaceutical industry ― by rejecting its attempts to protect profits at the expense of rural Oklahomans' access to health care.
The same industry that spends billions convincing you to buy their latest drugs is working behind the scenes to block hospitals and federally qualified health centers (FQHCs) from fully participating in the federal 340B drug program. Established by Congress over 30 years ago, 340B requires drug manufacturers to sell medications at reduced prices to qualifying hospitals and FQHCs, ensuring vulnerable communities have access to affordable care. Critical access hospitals (CAHs), which serve our most rural areas, automatically qualify ― yet the pharmaceutical industry is attempting to curtail their participation.
This program costs taxpayers nothing. It's strictly regulated and subject to rigorous federal oversight. But that hasn't stopped Big Pharma from bankrolling misleading campaigns to manipulate public opinion and intimidate state lawmakers against supporting HB 2048. Authored by Rep. Preston Stinson and Sen. Brent Howard, the bill would ensure hospitals and FQHCs can fully participate in the program, safeguarding health care access across Oklahoma. Earlier this session, out-of-state pharma executives flew into our state to pressure lawmakers against supporting the bill. Their tactics backfired. The Oklahoma House of Representatives soundly passed the bill, rejecting Big Pharma's deception, and Oklahomans should, too.
The same industry responsible for 300,000 opioid deaths is using its financial influence to deploy so-called 'patient advocacy' groups to defend its obstruction to this vital program. These organizations, funded by Big Pharma, protect industry profits, not patients.
More: My daughter has Type 1 diabetes. New bill will hurt vulnerable patients like her. | Opinion
Consider diabetes. Three companies control 90% of the insulin market, yet they charge Oklahomans nearly 10 times what patients in other countries pay. According to the OECD, the U.S. manufacturer price for insulin averages $98.70, compared to just $8.81 in other countries. For those with Type 2 diabetes, semaglutide medications offer hope. But once again, Big Pharma exploits American consumers. According to the Peterson-KFF Health System Tracker, the list price for Ozempic is $936 per month in the U.S. ― five times the price in Japan and 10 times that in Europe or Australia.
Oklahoma ranks fourth nationally in diabetes mortality, yet residents pay more for life-saving medication. Under Big Pharma's rules, Americans pay retail while the rest of the world pays wholesale.
Last year, a federal appeals court upheld Louisiana's 340B protections. Oklahoma's proposed law mirrors Louisiana's, yet Big Pharma continues fighting nationwide to block access to this vital program ― including here in Oklahoma. Don't be fooled by dark money ads and pharma-funded advocacy groups that vilify our rural hospitals and FQHCs. It's time to put Oklahoma patients first and stand up to a trillion-dollar industry that only shows up when their profits are at stake.
Rich Rasmussen is president and CEO of Oklahoma Hospital Association.
This article originally appeared on Oklahoman: Big Pharma trying to undermine Oklahoma's drug program | Opinion
